S&P Vs. Pharma Partnership Deal Volume
Pharma partnership deal volume was very positively correlated with the S&P Index for much of the past decade, but then followed an inverse correlation from around the time of the recession to the present day.
You may also be interested in...
Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.
In the current economy, e.l.f.’s value messaging is resonating with new consumers, contributing to an 8% jump in its fiscal 2021 first-quarter sales. The company expects continued volatility, but is optimistic about its robust digital game, growing skin-care clout and a newly announced partnership with Alicia Keys that it says will yield much more than “just another celebrity beauty line.”
Most of the major orthopaedics companies beat analyst expectations in the second quarter, but the ongoing COVID-19 pandemic raises uncertainties regarding procedure volumes for the rest of this year. See what Zimmer Biomet’s CEO Bryan Hanson said about it here.